



OFFICIAL

**RECEIVED
CENTRAL FAX CENTER**

Legal Division
Pfizer Inc.
235 East 42nd Street
New York, NY 10017

APR 19 2004

Facsimile Transmission

NOTICE OF CONFIDENTIALITY

This transmission is intended only for the use of the Addressee and may contain information that is: 1. Subject to attorney/client privilege; 2. Attorney work product; or 3. Confidential. If you are not the intended recipient, you are hereby notified that any dissemination, distribution or copying of the information contained in this facsimile is strictly unauthorized and prohibited. If you have received this facsimile in error, please notify us immediately by collect telephone call to the sender named below. Thank you.

To: EXAMINER JIANG

Location: USPTO

Facsimile Telephone: 1-703-872-9306

No. of Pages: (including this page): 6

From: Andrea E. Dorigo, Esq. - REG. NO. 47,532

Department Name: Legal Division

Charge No.: 88424

Facsimile Telephone: (212) 573-1939

Date: April 19, 2004

Time (New York) 10:34 AM

TO CONFIRM RECEIPT OF TRANSMISSION, CALL 212 733-1898 or 212-733-1898

Re: PC10244A - DECLARATION

FAX COVER SHEET (LEGAL DIVISION), 3/99

Attorney Docket No. PC10244A USA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:	Obach, R. S.	:	Examiner: Jiang
APPLICATION NO.:	09/528,978	:	Group Art Unit: 1617
FILING DATE:	3/21/2000	:	
TITLE:	USE OF CYP2D6 INHIBITORS IN COMBINATION THERAPIES	:	

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUBMISSION OF DECLARATION UNDER 37 CFR 1.132

Sir:

Applicants submit herewith a Declaration under 37 CFR 1.132 following a telephone communication by Examiner Jiang to the undersigned attorney for Applicants.

A Declaration under 37 CFR 1.132 was originally filed on December 18 2003 together with a Response to the Final Official Action. According to the telephone communication by Examiner Jiang to the undersigned attorney for Applicants referred to above, the Declaration filed was not persuasive. Accordingly, Applicants submit a new Declaration under 37 CFR 1.132, which is enclosed herewith.

In view of the foregoing, allowance of Claim 1, pending in the application, is respectfully requested.


USER\SDOCS\LA21952\LP\AEDM4\rg011.DOC / 223910

Attorney Docket No. PC10244A USA

The Commissioner is hereby authorized to charge any fees required under 37 C.F.R.
§§1.16 and 1.17 or to credit any overpayment to Deposit Account No. 16-1445.

Respectfully submitted,

Date: April 9, 2004



Andrea Dorigo
Attorney for Applicant(s)
Reg. No. 47,532

Pfizer Inc
Patent Department
150 East 42nd Street - 5th Floor
New York, NY 10017-5755
(212) 733-1898